Daiichi Sankyo Files For Japan Approval Of Anti-Coagulant Drug
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo has applied to market its anti-clotting edoxaban in Japan, with hopes of having it on the market in 2012